TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$251 Million

Seer

Follow-on Offering

Bookrunner, January 2021

Seer, Inc. aims to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological information. The Company’s initial product, the Proteograph Product Suite (Proteograph), will leverage the Company’s proprietary, engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome, and Seer believes it has the potential to impact a broad spectrum of the life sciences field. The Company believes that characterizing and understanding the full complexity of the proteome is foundational for accelerating biological insights and leads to broad potential end markets for proteomics, encompassing basic research and discovery, translational research, diagnostics, applied and industrial markets.